Replies to post #90353 on Biotech Values

[DewDiligence]

I find it hard to believe that D-mab has a net negative effect on metastatic cancers, as the author of your post is suggesting. Possible, yes, but highly unlikely, IMHO.

As for the pricing decisions if D-mab should obtain approval in both cancer and osteoporosis: AMGN should be so lucky to have this dilemma!